NCT06500234 Nutrition Impact on Immunotherapy of Cancer
| NCT ID | NCT06500234 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Qingdao Central Hospital |
| Condition | Nutrition Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 300 participants in total. It began in 2024-06-01 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates nutritional status and outcomes of immuntherapy in cancer patients.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of cancer, malnutrition Age \>18 years Performance status ECOG of 0 or 2. Life expectancy ≥ 6 months. At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment Postmenopausal or evidence of non-childbearing status for women of childbearing potential Patient is willing and able to comply with the protocol for the duration of the study. For all oral medications patients must be able to comfortably swallow capsules; Exclusion Criteria: * Patients unable to swallow orally administered medication and patients with Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs History of allogenic organ, bone marrow or double umbilical cord blood transplantation. Active or prior documented autoimmune or inflammatory disorders Uncontrolled intercurrent illness or patient considered a poor medical risk due to a serious, uncontrolled medical disorder, including but not limited to, ongoing or active infection, symptomatic congestive heart failure Currently taking medications with known risk of prolonging the QT interval or inducing Torsades de Pointes.
Contact & Investigator
chunling zhang, MD
STUDY CHAIR
Qingdao Central Hospital
Frequently Asked Questions
Who can join the NCT06500234 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Nutrition Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06500234 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 300 participants.
Is NCT06500234 currently recruiting?
Yes, NCT06500234 is actively recruiting participants. Contact the research team at niekeke@uor.edu.cn for enrollment information.
Where is the NCT06500234 trial being conducted?
This trial is being conducted at Qingdao, China.
Who is sponsoring the NCT06500234 clinical trial?
NCT06500234 is sponsored by Qingdao Central Hospital. The principal investigator is chunling zhang, MD at Qingdao Central Hospital. The trial plans to enroll 300 participants.